Brainstorm Cell reports FY2024 net loss $11.6M; cash only $0.4M; raises $1.64M via warrant inducement

BRAINSTORM CELL THERAPEUTICS INC.

2025-Q1 EPS reported -$0.45 vs consensus -$0.99 ▲ beat (+54.5%)

Net loss of $11.6M ($2.31 per share) improved from $17.2M loss ($6.00 per share) in 2023.
Cash and short-term deposits fell to $0.4M at year-end from $1.5M; company entered warrant inducement to raise ~$1.64M on April 1.
R&D spending reduced to $4.7M from $10.7M; G&A also cut to $7.0M from $10.7M.
Phase 3b trial of NurOwn for ALS proceeding with FDA SPA; partnership with Pluri for manufacturing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.